Jenburkt Pharmaceuticals Ltd, a active public limited company, was established on 10 June 1985 in Mumbai, Maharashtra, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: L24230MH1985PLC036541. Registered under ROC Roc Mumbai. it is listed on BSE: 524731. It has an authorized capital of ₹10.00 Cr and a paid-up capital of ₹4.41 Cr.
Formerly known as Jen Burkt Pharmaceuticals Private Limited. It upholds a compliant status. In 2024, it reported revenue of ₹146.63 Cr and a net worth of ₹144.94 Cr. Employing 765 professional, Its leadership includes Ashish Uttam Bhuta (Managing Director), Sumit Ajaybhai Thakkar (Director), Krishnan Subharaman (Director). Past directors included Ashish Uttam Bhuta, Devangi Sanjeev Shah, Krishnan Subharaman. It holds ₹2.03 Cr open charges and ₹16.17 Cr settled loans. Its latest AGM occurred on 18 July 2025, with the balance sheet filed on 31 March 2025. It is based at Nirmala Apts 93 Jay Prakash Rd Andheri W, Mumbai, Maharashtra, 400058.
L24230MH1985PLC036541
036541
10 June 1985
₹10.00 Cr
₹4.41 Cr
Roc Mumbai
Listed (BSE: 524731)
Active
Explore comprehensive insights into Jenburkt Pharmaceuticals Ltd — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ashish Uttam Bhuta | Managing Director | 02 Jun 2007 | Current |
| Sumit Ajaybhai Thakkar | Director | 26 Jul 2023 | Current |
| Krishnan Subharaman | Director | 28 May 2024 | Current |
| Hina Ravindra Mehta | Director | 28 Mar 2020 | Current |
| Pankaj Arun Dantwala | Director | 28 May 2024 | Current |
| Dilip Harkishandas Bhuta | Whole-Time Director | 16 Jul 2013 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Whole-Time Director | 16 Jul 2013 | Past |
| Pramod Abcsdd | Additional Director | 05 May 2015 | Past |
| Pramod Abcsdd | Additional Director | 29 Jul 2024 | Past |
| Pramod Abcsdd | Additional Director | 01 Sep 2020 | Past |
| Pramod Abcsdd | Director | 23 Jul 2018 | Past |
| Pramod Abcsdd | Managing Director | 13 Jun 2013 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Jenburkt Pharmaceuticals Ltd, for the financial year ended 2024, experienced modest growth in revenue, with a 3.36% increase. The company also saw a slight improvement in profitability, with a 5.57% increase in profit. The company's net worth Soared by an impressive increase of 18.43%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Jenburkt Pharmaceuticals had a promoter holding of 47.56% and a public holding of 52.44%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹20,300,000.00
₹161,734,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Nov 2022 | Others | ₹2.00 Cr | Open |
| 21 Nov 2022 | Others | ₹0.20 M | Open |
| 21 Nov 2022 | Others | ₹0.10 M | Open |
| 02 Dec 2022 | Others | ₹3.00 Cr | Satisfied |
| 21 Oct 2022 | Others | ₹0.15 M | Satisfied |
Explore comprehensive loan charge details -
Jenburkt Pharmaceuticals has a workforce of 765 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Jenburkt Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jenburkt Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
A charge registered on 28 Aug 2019 via Charge ID 100289026 with Others was fully satisfied on 29 Oct 2025. was recorded as a recent event.
Jenburkt Pharmaceuticals Ltd last Annual general meeting of members was held on 18 Jul 2025 as per latest MCA records. was recorded as a recent event.
Jenburkt Pharmaceuticals Ltd has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai. was recorded as a recent event.
Progress on A charge registered on 21 Oct 2022 via Charge ID 100627860 with Others was fully satisfied on 22 Jan 2025. was documented.
Progress on Krishnan Subharaman was appointed as a Director was appointed as a Director on 28 May 2024 & has been associated with this company since 1 year 6 months . was documented.
Pankaj Arun Dantwala was appointed as a Director was appointed as a Director on 28 May 2024 & has been associated with this company since 1 year 6 months . was recorded as a recent event.
When Jenburkt Pharma wants to buy back their shares, they're offering a price of Rs. 576 per share, which is 22.37% higher than the current market price. This buyback is for 208333 shares and will be done through a Tender Offer. The total cost is Rs. 12 Crore, but doesn't include extra expenses. The Board formed a committee to handle the buyback and it's subject to shareholder approval. Yes Securities (India) Limited will manage the buyback..
The CIN of Jenburkt Pharmaceuticals Ltd is L24230MH1985PLC036541.
Jenburkt Pharmaceuticals Ltd is headquartered at Nirmala Apts 93 Jay Prakash Rd Andheri W, Mumbai, Maharashtra, 400058.
Jenburkt Pharmaceuticals Ltd was incorporated on 10 June 1985.
The current directors of Jenburkt Pharmaceuticals Ltd are
The primary industry of Jenburkt Pharmaceuticals Ltd is Manufacturing.
Jenburkt Pharmaceuticals Ltd is listed. It is listed on BSE: 524731.
The authorized capital of Jenburkt Pharmaceuticals Ltd is ₹10.00 Cr, and the paid-up capital is ₹4.41 Cr.
The compliance status of Jenburkt Pharmaceuticals Ltd is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX